Friday broker round-up
(Sharecast News) - William Hill: Peel Hunt upgrades to hold with a target price of 305p.
Read moreTue, 19th Jul 2011 12:07
(Sharecast News) - William Hill: Peel Hunt upgrades to hold with a target price of 305p.
Read moreLONDON (Alliance News) - Evgen Pharma PLC said Thursday it expects to receive the final read-out from two clinical trials by the end of 2018.The drug development company said at its annual
Read more(Sharecast News) - Clinical-stage drug development company Evgen Pharma has concluded patient recruitment in its STEM Phase IIa trial of SFX-01 in metastatic breast cancer, it announced on Wednesday.
Read more(Sharecast News) - Unite Group: Numis downgrades to hold with a target price of 900p.
Read moreLONDON (Alliance News) - Evgen Pharma PLC said Wednesday it has concluded its patient recruitment for its STEM Phase IIa trial of SFX-01 in metastatic breast cancer.Following the favourable
Read moreFriday 20 JulyHomeserveKCOM GroupMonday 23 JulyEthernity Energy 24
Read moreLONDON (Alliance News) - Clinical drug development company Evgen Pharma PLC said Wednesday its annual loss narrowed in line with expectations.Evgen, which focuses on cancer and neurological
Read moreLONDON (Alliance News) - Evgen Pharma PLC said Monday its STEM trial showed "early signs of anti-tumour activity" in breast cancer patients.STEM is the company's study of in a
Read moreLONDON (Alliance News) - Drug development company Evgen Pharma said Wednesday that it has secured a European patent recognising its intellectual property for a method of stabilising sulforaphane,
Read moreLONDON (Alliance News) - Drug development company Evgen Pharma PLC has started a new research collaboration with Imperial College London focusing on SFX-01, the company's
Read more(ShareCast News) - AIM-listed Evgen Pharma has signed a services agreement with a consortium of Cheshire-based drug developments firms for its sulforaphane product. APT Trans, the consortium of drug developers based in the Biohub at Alderley Park, which comprises of Aptus Clinical, Apconix and Seda
Read more(ShareCast News) - Clinical-stage drug development company Evgen Pharma announced the appointment of experienced healthcare executive Richard Moulson as its chief financial officer on Tuesday. The AIM-traded firm said Moulson was joining immediately as CFO-designate for a handover period to 28 Febru
Read more(ShareCast News) - Evgen Pharma, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has received a positive interim safety review from the independent Data Safety Monitoring Board (DSMB) for its Phase II double-blind placebo-controlled SAS trial
Read more(ShareCast News) - Clinical stage drug development company Evgen Pharma announced on Wednesday that it has received a Clinical Trial Approval from the UK's regulatory agency for the commencement of its Phase II clinical trial of SFX-01 in breast cancer. The AIM-traded firm said patient recruitment w
Read more